BridgeBio Pharma Inc (NASDAQ: BBIO) is -34.51% lower on its value in year-to-date trading and has touched a low of $21.62 and a high of $44.32 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BBIO stock was last observed hovering at around $27.19 in the last trading session, with the day’s loss setting it -0.75%.
Currently trading at $26.44, the stock is 7.14% and 5.89% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.32 million and changing -2.76% at the moment leaves the stock -2.71% off its SMA200. BBIO registered -11.25% loss for a year compared to 6-month loss of -4.24%. The firm has a 50-day simple moving average (SMA 50) of $24.9758 and a 200-day simple moving average (SMA200) of $27.222225.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 8.18% gain in the last 1 month and extending the period to 3 months gives it a 6.18%, and is 17.30% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.33% over the week and 6.30% over the month.
BridgeBio Pharma Inc (BBIO) has around 550 employees, a market worth around $5.00B and $217.76M in sales. Profit margin for the company is -201.53%. Distance from 52-week low is 22.29% and -40.34% from its 52-week high. The company has generated returns on investments over the last 12 months (-88.62%).
with sales reaching $44.84M over the same period.The EPS is expected to grow by 34.89% this year, but quarterly earnings will post 3,201.43% year-over-year. Quarterly sales are estimated to grow 2,469.50% in year-over-year returns.
BridgeBio Pharma Inc (BBIO) Top Institutional Holders
349.0 institutions hold shares in BridgeBio Pharma Inc (BBIO), with institutional investors hold 99.84% of the company’s shares. The shares outstanding are 175.08M, and float is at 147.54M with Short Float at 11.66%. Institutions hold 94.45% of the Float.
The top institutional shareholder in the company is KOHLBERG KRAVIS ROBERTS & CO. L.P. with over 31.06 million shares valued at $786.77 million. The investor’s holdings represent 16.5582% of the BBIO Shares outstanding. As of 2024-06-30, the second largest holder is VIKING GLOBAL INVESTORS LP with 25.12 million shares valued at $636.31 million to account for 13.3917 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 14.05 million shares representing 7.4924% and valued at over $356.01 million, while BLACKROCK INC. holds 6.636 of the shares totaling 12.45 million with a market value of $315.31 million.
BridgeBio Pharma Inc (BBIO) Insider Activity
The most recent transaction is an insider sale by Kumar Neil, the company’s Chief Executive Officer. SEC filings show that Kumar Neil sold 27,389 shares of the company’s common stock on Nov 19 ’24 at a price of $22.41 per share for a total of $0.61 million. Following the sale, the insider now owns 4.9 million shares.
BridgeBio Pharma Inc disclosed in a document filed with the SEC on Nov 19 ’24 that STEPHENSON BRIAN C (Secretary, Treasurer & CFO) sold a total of 4,156 shares of the company’s common stock. The trade occurred on Nov 19 ’24 and was made at $22.41 per share for $93137.0. Following the transaction, the insider now directly holds 93758.0 shares of the BBIO stock.
Still, SEC filings show that on Nov 19 ’24, BRIAN STEPHENSON (Officer) Proposed Sale 4,156 shares at an average price of $22.35 for $92887.0. The insider now directly holds shares of BridgeBio Pharma Inc (BBIO).
